Fennec Pharmaceuticals Inc. Common Stock (FENC)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and sell at sensible prices. Fennec is not that yet. It is a commercial-stage biopharma with one main product, PEDMARK, for a narrow pediatric oncology use, sold by a 35-person organization. That niche is specialized, but a single product and tiny headcount mean the moat is narrow at best. The recent trend is encouraging: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $17.9M, net income $2.0M, and diluted EPS $0.05; in fiscal Q1 2026, revenue was $15.1M and net income $201,000. But the annual record is uneven. FY2025 revenue was $44.6M, down from $47.5M in FY2024, and the net loss widened to $9.7M, or $0.34 per diluted share, from a $436,000 loss in FY2024. FY2023 had revenue of $23.8M and a $16.0M net loss. FairStock's Peter Lynch category is none because the company lost money in each of the last four years, though the most recent quarters hint at a turn. The balance sheet does not look distressed by Altman Z-Score of 3.49, and trailing free cash flow is only about -$2.0M, but Piotroski is 4/9. Valuation is not Graham-like: at the 2026-10-13 close of $10.18, P/B is 8.41, the P/E is negative at -84.83, and FCF yield is -0.6%. I see a speculative commercial turnaround, not a proven value compounder. The key question is whether recent profitability is durable or merely a brief window.

In plain English: Fennec Pharmaceuticals is a small healthcare company that sells PEDMARK, a treatment intended to help prevent hearing loss in children receiving cisplatin chemotherapy. The business is not yet consistently profitable, though its latest reported quarter showed a profit and strong sales growth from a year earlier. Based on its reported numbers and the 2026-10-13 stock price of $10.18, the shares do not look clearly cheap; they carry a high price relative to the company's book value and recent losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer